Novartis, Australia & New Zealand

Politeness can be a clinical blind spot. Some patients with CML-CP may accept ongoing side effects over time or minimise them in consultations. Encouraging patients to track symptoms between visits may help reveal what routine check-ins can miss. And support more informed conversations about their lived experience. This content is intended to support clinician education and clinician–patient communication in CML. ©2026 Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. Sydney NSW. AU-30803. Ward7 NOSC39435M. July 2026.

Some patients with CML-CP can downplay ongoing side effects despite impact on quality of life. Encourage an honest conversation. This content is intended to support clinician education and clinician–patient communication in CML.

A patient’s politeness may be hiding more than you think. Those with CML-CP may become accustomed to ongoing side effects and stop mentioning them during consultations. What appears manageable on the surface may be affecting quality of life. Encouraging symptom tracking between visits may help bring hidden treatment burden into the conversation. This content is intended to support clinician education and clinician–patient communication in CML. ©2026 Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. Sydney NSW. AU-30803. Ward7 NOSC39435M. July 2026.

What appears manageable on the surface may still be affecting your CML-CP patients’ quality of life. This content is intended to support clinician education and clinician–patient communication in CML.

Dear %JOBTITLE% %LASTNAME%, Patients not meeting their LDL-C targets no matter what you do? Join your colleagues and a local cardiologist at the ‘Shifting the needle in ASCVD management’ meeting for a discourse on the why and how behind low LDL-C targets. Discover and discuss: • The importance of LDL-C in ASCVD • The benefits of treatment for both you and your patients • How you can optimise patient treatment in your practice Space is limited so reserve your spot now to help your patients achieve and maintain their LDL-C targets.

Dear %JOBTITLE% %LASTNAME%, Looking to upgrade LDL-C control in your patients? The ‘Shifting the needle in ASCVD management’ meeting is an opportunity to discuss difficult-to-reach LDC targets and how to achieve them with your colleagues and a local cardiologist. To help you shift the needle for your patients this meeting will cover: • The importance of LDL-C in ASCVD • The benefits of treatment for both you and your patients • How you can optimise patient treatment in your practice Space is limited so reserve your spot now to help your patients achieve and maintain their LDL-C targets.